The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.
I n August 2014, after the current outbreak of Ebola virus disease was declared a public health emergency of international concern by the World Health Organization (WHO), the Canadian government donated 800 vials of the replication-competent recombinant vesicular stomatitis virus (rVSV)-vectored Zaire ebolavirus (rVSV-ZEBOV) candidate vaccine to the WHO. The VSV Ebola Consortium (VEBCON) was created under the auspices of the WHO to initiate phase 1 studies to facilitate rapid progression to phase 2 and 3 trials in affected countries. 1 Live replicating viral vaccines elicit humoral and cellular immune responses against viral pathogens. 2,3 A single injection of 10 million plaque-forming units (PFU) of rVSV-ZEBOV protected nonhuman primates exposed to lethal doses of Zaire ebolavirus. [4] [5] [6] [7] Vesicular stomatitis virus belongs to the Rhabdoviridae family. 8 In livestock, wild-type VSV causes vesicles and ulcerations of the oral tissues, feet, and teats. 9 Human infections are rare and asymptomatic or typically cause mild influenza-like illness, although more severe infections have been described. [9] [10] [11] [12] [13] [14] The wild-type virus is not endemic in Africa and Europe. 15, 16 The preclinical safety record of the rVSV vector is encouraging: among roughly 80 immunized nonhuman primates, none had detectable toxic effects. 3 Viremia associated with rVSV-ZEBOV was detected on day 2 only, suggesting rapid viral clearance through the innate immune response. Safety in immunocompromised hosts was assessed in a few nonhuman primates infected with the human immunodeficiency virus 6 and in mice with severe combined immunodeficiency. 17 None of the animals had detectable illness after immunization. Viral shedding in saliva and urine was not observed. 3 To assess the safety and immunogenicity of various doses of rVSV-ZEBOV in countries with or without previous outbreaks of Ebola virus disease, we initiated parallel, harmonized VEBCON trials in Lambaréné, Gabon; Kilifi, Kenya; Hamburg, Germany; and Geneva. We report the initial safety and immunogenicity data emerging from these ongoing studies.
Me thods

Study Designs and Participants
The studies in Lambaréné, Kilifi, and Hamburg were open-label, uncontrolled, phase 1 trials de-signed to assess the safety, side-effect profiles, and immunogenicity of ascending doses of rVSV-ZEBOV vaccine (BPSC1001) at doses ranging from 300,000 to 20 million PFU in healthy adults of both sexes between the ages of 18 and 55 years. The Geneva study was a double-blind, randomized, placebo-controlled, phase 1 trial assessing the safety and immunogenicity of the rVSV-ZEBOV vaccine at doses of 10 million and 50 million PFU in healthy adults between the ages of 18 and 65 years. Full details regarding the study centers, entry criteria, and procedures are provided in the individual study protocols, available with the full text of this article at NEJM.org. The studies were reviewed and approved by the respective national competent authorities, local ethics committees, the German authority for genetic engineering, and the WHO research ethics review committee. All the participants provided written informed consent. An independent consortium-wide data and safety monitoring board provided oversight.
All four studies were investigator-initiated trials sponsored by each local institution. The Wellcome Trust provided funding through a grant to the WHO. Other individual funding sources are outlined in the Supplementary Appendix, available at NEJM.org. A total of 800 vaccine doses were donated to the WHO by the Public Health Agency of Canada. Funding bodies and the vaccine manufacturers were not involved in the analysis of the data, nor did they contribute to the preparation or writing of the manuscript.
Vaccine and Placebo
The rVSV-ZEBOV vaccine was developed by the Canadian National Microbiology Laboratory and was licensed to BioProtection Systems (a subsidiary of NewLink Genetics). The vaccine was subsequently sublicensed to Merck, which has assumed responsibility for ongoing research and development. The vaccine was manufactured at IDT Biologika in Dessau-Rosslau, Germany, and stored in a manner consistent with good manufacturing practices. The same lot (no. 003 05 13), which was dispensed in single-dose vials as 100 million PFU per milliliter, was sent from Canada to Geneva and subsequently to the other sites. (Additional details regarding reconstitution are provided in the Supplementary Appendix.) Placebo syringes containing 0.5 ml of saline were packaged identically.
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Vaccination
Injections were administered intramuscularly into the deltoid. Dose-escalation studies were staggered (for details, see the Methods section in the Supplementary Appendix). In the Lambaréné cohort, participants received doses of 300,000 PFU or 3 million PFU. In Hamburg, participants received doses of 3 million PFU or 20 million PFU. In Kilifi, participants received a dose of 3 million PFU. In Geneva, the first 19 run-in participants received a single openlabel injection of 10 million PFU and were observed for at least 1 week. Thereafter, participants who were planning to deploy to Ebola-affected regions were randomly assigned in a 1:1 ratio in a double-blind fashion to receive a vaccine dose of either 10 million PFU or 50 million PFU, whereas those who were not planning to deploy to such regions were randomly assigned in a 1:1:1 ratio to receive either vaccine dose or placebo. (An overview of the four trials is provided in Fig. S4 in the Supplementary Appendix.)
Safety Monitoring
Injection-site and systemic reactogenicity and medication use were recorded for 7 days after injection and at follow-up (days 14 and 28). Clinical and laboratory evaluations were performed during each study visit (for details, see the Methods section in the Supplementary Appendix). Laboratory analyses included a complete blood count and measurements of creatinine, C-reactive protein, and liver function. Adverse events were listed for each participant according to the Common Terminology Criteria for Adverse Events and the Medical Dictionary for Regulatory Activities and are reported individually and in aggregate.
INVESTIGATION OF ARTHRITIS AND SKIN LESIONS
After the observation of arthralgia in some Geneva participants, all but the first participant with swollen joints or axial involvement in Geneva underwent joint imaging (by means of ultrasonography or magnetic resonance imaging [MRI]), and all but two participants were referred to a rheumatologist. Arthritis was confirmed if the study team observed swelling or imaging revealed effusion. Participants in Geneva who had skin lesions underwent biopsy, swabbing, or puncture of lesions.
Detection of rVSV
We developed quantitative reverse-transcriptasepolymerase-chain-reaction (RT-PCR) assays (TaqMan) targeting the VSV nucleoprotein gene (see the Methods section in the Supplementary Appendix). Results are expressed in copies per milliliter. In the dose-escalations trials, rVSV viral loads were monitored from day 0 to day 28, including daily sampling of plasma, urine, and saliva through day 7 in Hamburg. In Lambaréné and Kilifi, total RNA from plasma, urine (400 µl), and saliva (200 µl) (Viral Transport Kit, BD) was stored in TRIzol LS Reagent (Life Technologies) and analyzed at St. George's University of London. In Hamburg, samples were assessed on site. In Geneva, RT-PCR was performed on days 1, 3, and 7 on all plasma specimens, on saliva and urine in the first 20 participants vaccinated with 10 million PFU and 10 participants vaccinated with 50 million PFU, and later on skin vesicles and synovial fluid. RT-PCR assay to detect rVSV was performed on oral lesions observed in Hamburg and Geneva. Virus isolation was performed in Geneva by means of plaque assay on Vero E6 cells from selected samples and confirmed on PCR and immunostaining (see the Methods section in the Supplementary Appendix).
Immunogenicity
We assessed serum samples on days 0 and 28 after injection. We performed the enzyme-linked immunosorbent assay (ELISA) for ZEBOV-glycoprotein-specific antibodies using the homologous Zaire-Kikwit strain glycoprotein (following the standard operating procedure of the U.S. Army Medical Research Institute of Infectious Diseases [SOP AP-03-35-00]) or inactivated whole virions of the Zaire-Guéckédou strain. The relative amounts of ZEBOV-glycoprotein-specific antibodies were reported as end-point titers or geometric mean concentration of arbitrary ELISA units per milliliter. Neutralizing antibodies were detected with the use of VSV pseudovirions expressing the luciferase reporter gene complemented by glycoprotein from the ZEBOV 95 Kikwit strain, as described previously, 18 or infectious ZEBOV isolate Mayinga. (For detailed descriptions, see the Methods section in the Supplementary Appendix.)
Statistical Analysis
We determined the frequencies of all adverse events according to study center and dose group. Categorical variables are described with counts and percentages, and continuous variables with means and standard deviations or medians and interquartile ranges for skewed variables. Antibody responses are reported as the geometric mean titer or geometric mean concentration with 95% confidence intervals. We obtained reverse cumulative distributions by plotting for each possible value of the titer the proportion of participants with a titer greater than this value. We used Fisher's exact test, the Mann-Whitney test, and the Kruskal-Wallis test or Spearman's correlation coefficient to calculate intergroup associations. For immunogenicity, we compared geometric mean titers or concentrations, seropositivity rates, and seroresponse rates between days 0 and 28 using Wilcoxon's test for paired data and McNemar's test. We used Spearman's correlation coefficient to assess the correlation between assays. Although at the time of this analysis clinical investigators and participants in the randomized, controlled trial were unaware of study-group assignments, the blind was broken after the 3-month visit for the 11 participants with arthritis. The statistical analysis plans are provided in the study protocols at NEJM.org.
R esults
Study Populations
A total of 158 participants received either vaccine (150 participants) or placebo (8 participants) in the three dose-escalation studies from November 17, 2014, through January 19, 2015, and in the Geneva randomized, controlled trial from November 10, 2014, through December 9, 2014, before a safety-driven study hold and subsequent resumption of vaccination with a lower dose (3 million PFU) ( Fig. S4 in the Supplementary Appendix). The study populations are described in Table 1 , and in Table S2 in the Supplementary Appendix. In Geneva, the run-in participants and those who underwent randomization were compared for baseline characteristics and adverseevent outcomes. In the absence of significant differences, pooled results are reported. Vaccine was administered in doses as follows: 300,000 PFU in 20 participants, 3 million PFU in 49 participants, 10 million PFU in 35 participants, 20 million PFU in 30 participants, and 50 million PFU in 16 participants. A total of 138 participants had been followed for at least 4 weeks at the time of this analysis ( Fig. S4 in the Supplementary Appendix). The results reported here are from interim databases for ongoing trials.
Safety
Serious Adverse Events
There were no serious adverse events associated with the vaccine. Three hospitalizations due to malaria occurred in Lambaréné.
Acute Reactogenicity
Solicited and unsolicited adverse events were frequent ( Table 2 ). Of the 138 participants who were followed for at least 4 weeks, 124 (90%) had at least one adverse event, with the majority of events reported as mild or moderate. Grade 3 symptoms were reported in 3 of 20 participants (15%) in Kilifi, 2 of 20 (10%) in Hamburg, and 12 of 51 (24%) in Geneva; none were reported in Lambaréné. Local reactogenicity was common but generally mild. Most adverse events appeared early (median, 1 day; interquartile range, <24 hours to 1 day), subsided rapidly (median, 1 day; interquartile range, <24 hours to 1 day), and were alleviated with the use of acetaminophen or nonsteroidal antiinflammatory drugs as needed. The incidence and intensity of the events varied according to both the dose and the study site: objective fever was reported in 5 of 20 participants (25%) in Hamburg, 13 of 51 (25%) in Geneva, 6 of 20 (30%) in Kilifi, and 2 of 39 (5%) in Lambaréné. At a given dose, such as 3 million PFU, inflammatory reactions were more frequently reported in hospitalized participants in Hamburg than in Lambaréné ( Table 2) .
Biologic Monitoring
Hematologic changes were observed in all participants who were monitored during the first days after vaccination ( Table S3 in the Supplementary Appendix). In Lambaréné, transient leukocytopenia was observed in 12 of 20 participants (60%) receiving 300,000 PFU and 8 of 19 participants (42%) receiving 3 million PFU; lymphocytopenia was observed in 2 of 19 participants (11%) in the group receiving 3 million PFU. In Hamburg, an asymptomatic drop in the number of circulating lymphocytes was observed 1 day after vaccination in all participants and was resolved by day 2 (P<0.01 for the compari-son between screening vs. day 1). The decrease was unrelated to dose, reactogenicity, or substantial viremia, indicating biologic activity even at a dose of 3 million PFU. Among the 51 participants in Geneva, 36 (71%) had a decreased number of circulating lymphocytes on day 1, and 27 (53%) had a decreased number of neutrophils on day 3, with rapid resolution of both conditions ( Table S3 in the Supplementary Appendix). Monocytosis on day 3 and a transient reduction in platelets were also observed. Liverfunction and creatinine levels remained unchanged.
Viremia and Viral Shedding
Low levels of rVSV-ZEBOV RNA were identified in plasma on RT-PCR assay on days 1 to 3 in most participants who were tested ( Fig. 1, and Table  S4 in the Supplementary Appendix). Participants with positive results for rVSV on PCR assay ranged from 8 of 20 (40%) among Lambaréné vaccinees immunized with 300,000 PFU to 42 of 51 (82%) among Geneva vaccinees. In Lambaréné, 18 of 19 participants (95%) who received a dose of 3 million PFU had detectable viremia on day 1 or 2; 15 of 19 participants (79%) had complete resolution by day 7. The same pattern was observed in Kilifi, where 18 of 20 participants (90%) had values that were below the detection level by day 7. In Hamburg, all participants who received doses of 3 million PFU and 20 million PFU who were monitored daily until day 7 had detectable viremia, with peaks on day 2 or 3 and complete resolution by day 5.
All but eight plasma specimens from all studies were negative by day 7, and infectious virus was not recovered from any blood specimen tested. In the Geneva study, there was no correlation between peak viremia and vaccine dose, age, sex, frequency or intensity of adverse events, or lymphocytopenia. Viral RNA was not detected in saliva or urine samples at any site; occasional oral lesions ( Table 2) were all negative for rVSV on PCR assay.
Arthritis
In Geneva, 11 of 51 participants (22%) with no previous history of joint disease had an onset of arthralgia a median of 11 days (interquartile range, 9 to 13) after injection; 8 participants had received 10 million PFU and 3 had received 50 million PFU. These participants presented with asymmetric involvement of a median of 2 (range, 1 to 4) peripheral joints, with swelling on physical examination and as seen on ultrasonography as tenosynovitis or bursitis in at least 1 joint (Table S5 in the Supplementary Appendix). Three participants had axial involvement; of these, 1 had evidence of arthritis on MRI. Thus, arthritis was confirmed in 9 of 11 participants. Pain was 9
Skin Lesions
Among the 11 participants in Geneva with arthritis, a mild maculopapular rash mainly on the limbs developed in 3 participants between days 7 and 9 and lasted 7 to 15 days ( Fig. 2A, subpanel  a) . The rash was associated with a few tender vesicles on fingers or toes (Fig. 2B, subpanel d) .
Histologic analysis of one papule revealed a dermal T-lymphocytic infiltrate ( Fig. 2A, subpanels  b and c) . Vesicular lesions reflected subepidermal dermatitis with necrotic keratinocytes (Fig. 2B, subpanel d) containing abundant VSV antigens (Fig. 2B, subpanel f) . 21 Among the 3 participants with rash, rVSV was identified on RT-PCR in all 3 up to day 17, and infectious rVSV was isolated from a specimen with the highest RNA level 9 days after immunization (Fig. 2C ). Concomitantly obtained plasma samples remained negative, showing local replication. At other VEBCON trial sites, investigators screened participants for rVSV-associated dermatologic findings, but none were observed. 
ZEBOV-Glycoprotein-Specific Antibody Responses
Serum antibodies induced by rVSV-ZEBOV were assessed with the use of four distinct assays. Baseline antibody levels were generally low, with outliers. Low-level baseline seropositivity was identified in 12 of 23 participants (52%) in Lambaréné ( Fig. 3A, and Tables S6 through S9 in the Supplementary Appendix). Four weeks after immunization, ZEBOV-glycoprotein-specific antibodies were detected on ELISA in all vaccinees with similar anti-glycoprotein geometric mean titers (Fig. 3A, and Table S6 in the Supplementary Appendix) and distribution, as seen on reverse cumulative distribution curves (Fig. 3E) . The lowest dose (300,000 PFU) was immunogenic in Lambaréné, with a higher proportion of participants with a low response than among those receiving higher doses ( Fig. 3A through 3D ). Rates of seropositivity (0 to 53%) and titers were lower with the use of whole-virion ELISA (Fig. 3B, and Table S7 and Fig. S5 in the Supplementary Appendix), which identified baseline antibodies reacting with nucleocapsid or matrix proteins, but not glycoprotein, in samples from Lambaréné (Fig. S6 in the Supplementary Appendix).
On pseudovirion neutralization assay assessing the 50% serum neutralization capacity (PsVNA50), neutralizing antibodies were absent at baseline (including among participants in Lambaréné) but were elicited in 76 of 91 vaccinees (84%) (Fig. 3C , and Table S8 in the Supplementary Appendix). With the use of infectious ZEBOV particles, lowlevel neutralizing antibodies (≥1:8) were detected at baseline in 6 of 20 participants (30%) in Hamburg, 3 of 20 (15%) in Kilifi, and 10 of 38 (26%) in Lambaréné (Fig. 3D, and Table S9 in the Supplementary Appendix). The two assays showed significant increases in neutralizing antibodies after any dose of rVSV-ZEBOV (Tables S8 and S9 in the Supplementary Appendix).
Despite strong correlations between antibody titers on glycoprotein ELISA and on PsVNA50 (Fig. S7 in the Supplementary Appendix) , significant differences were observed. In the Geneva study, a dose of 50 million PFU elicited similar titers of glycoprotein-binding antibodies as did 10 million PFU, with geometric mean titers of 1780 (95% confidence interval [CI], 1048 to 3022) and 1064 (95% CI, 757 to 1495), respectively, but significantly higher PsVNA50 antibody titers, with geometric mean titers of 273 (95% CI, 157 to 475) and 99 (95% CI, 62 to 159) (P = 0.02). The influence of increasing doses on the distribution of neutralizing antibodies was confirmed on reverse cumulative distribution ( Fig. 3F ) and correlation analyses (Tables S10 and S11 and Fig. S8 in the Supplementary Appendix). Thus, higher doses of rVSV-ZEBOV elicited similar glycoprotein-binding titers but higher neutralizing-antibody titers.
Discussion
The Zaire-variant candidate vaccine rVSV-ZEBOV expresses a viral surface glycoprotein that has immunogenic potential after a single dose for populations at risk for Ebola virus disease, as well as possibly for postexposure prophylaxis. 4, 7, 17, 22 It is a replication-competent chimeric virus for which human-safety data were limited to a single postexposure case report 21 at the time of the initiation of this study. We describe the safety and immunogenicity results for rVSV-ZEBOV in African and European populations, collected in four harmonized, ongoing trials, including three dose-escalating trials and one randomized, controlled trial.
Acute inflammatory symptoms were expected after immunization with rVSV-ZEBOV. The frequency and intensity of such symptoms were study-dependent. At a vaccine dose of 3 million PFU, objective fever was reported in 20 to 30% of vaccinees in Hamburg and Kilifi but in only 11% in Lambaréné. An influence of dose on adverse events was noted between a dose of 300,000 PFU and 3 million PFU in Lambaréné but not between higher doses at other sites. It is likely that the early onset, short duration, and responsiveness to symptomatic treatment of these symptoms will facilitate acceptance of the vaccine, but vaccine-induced fever should be anticipated if rVSV-ZEBOV is administered to contacts of patients infected with Ebola virus disease.
Levels of rVSV RNA were transiently detected in early blood samples, suggesting that innate responses, especially those involving the type I interferon pathway, help to limit viral replication. [23] [24] [25] [26] Viral seeding of joints and skin, mostly identified in the Geneva cohort, was unexpected. It showed that viral dissemination and replication can occur and persist for up to 2 to 3 weeks after immunization -in other words, that early innate responses may not always be sufficient for complete viral control. Replication appeared to be restricted to permissive tissues: viral RNA remained below detection in plasma and peripheral-blood mononuclear cells, and replicating virus was retrieved only from skin vesicles. Interestingly, skin vesicles in livestock infected with VSV or foot-and-mouth virus occur at similar locations, reflecting the relative resistance of keratinocytes to type I interferon. 27 The pattern of rVSV-ZEBOV replication in humans thus may be defined by the permissiveness of rVSV replication. 28, 29 In the Geneva cohort, arthritis was confirmed in 9 of 51 participants (18%) and suspected in another 2. Two cases were reported among 40 participants in Hamburg and Kilifi (5%), albeit at a lower intensity and of shorter duration than in Geneva. Possible mechanisms of virus-induced arthritis include autoimmunity, lytic effects of infected synovial cells, and the deposition of immune complexes. The induction of autoimmunity is not supported by the rapid onset (<2 weeks) and the lack of vaccine-induced pathogenic antibodies. We cannot rule out immune-complex deposition, but the detection of rVSV RNA in synovial fluid showed the seeding of rVSV-ZEBOV into joints. Since arthralgia or arthritis is not elicited by VSV and was not reported with other rVSV constructs that have been tested to date, the pathophysiology of the chimeric rVSV-ZEBOV vaccine may include features attributable to both its VSV and ZEBOV glycoprotein components. Although pain may be prolonged and relapse may occur, the prognosis of viral vaccine-induced arthritides is considered favorable on the basis of experience with rubella vaccination. 30 Accordingly, the VEBCON data and safety monitoring board concluded on January 1, 2015, that the trials could proceed as originally planned (including doses up to 100 million PFU) once informed-consent forms were updated.
The rVSV-ZEBOV vaccine generated glycoprotein-binding antibodies in all participants at any dose, showing its immunogenicity in humans. Doses containing as few as 300,000 PFU may be sufficient to elicit glycoprotein-binding antibodies. Preexisting antibodies to ZEBOV nucleocapsid or matrix proteins (Fig. S6 in the Supplementary Appendix) conferred no advantage for the induction of glycoprotein-specific responses. Neutralizing antibodies were also generated in most participants, and a dose-response effect was shown. Despite similar glycoprotein-binding antibody titers, higher vaccine doses elicited higher titers of neutralizing antibodies. Since the relative roles of neutralizing and glycoprotein-binding antibodies in protection against Ebola virus disease are unknown, we cannot conclude whether higher vaccine doses are required for optimal protection. A comparison of anti-glycoprotein antibody titers detected in this study (in the Hamburg cohort receiving 20 million PFU) with those reported with a chimpanzee adenovirus vector 31 revealed similar values. This finding suggests that the two vaccines that are currently undergoing testing in West Africa may induce humoral responses of the same order of magnitude.
These investigations have contributed to the dose-selection process performed by the vaccine manufacturers and have raised the awareness of investigators, members of institutional review boards, and regulators about the specific adverse events to be expected with the use of vaccines. They have also resulted in the introduction of safety-driven changes in the protocols for the ongoing phase 2 and 3 studies.
In conclusion, first results of rapidly implemented, parallel phase 1 studies including indepth safety investigations showed that the rVSV-ZEBOV vaccine is reactogenic but immunogenic at doses ranging from 300,000 to 50 million PFU in African and European volunteers, with higher titers of neutralizing antibodies at higher doses. The viral dissemination in skin and joints that was observed in some participants needs to be balanced with the possible benefit offered by this vaccine in the potential control of outbreaks of Ebola virus disease. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
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